A n intronic GGGGCC hexanucleotide (G4C2) expansion of >30 repeats found within C9orf72 is the most prominent mutation in familial FTD and ALS 1, 2 . These devastating neurodegenerative disorders represent a continuum of the same disease 3, 4 . While the presence of the expanded G4C2 repeat can confer toxicity through a number of aberrant pathways, amassing evidence suggests that gain-of-function mechanisms contribute [5] [6] [7] . The accumulation of sense-strand G4C2-containing and antisense-strand G2C4-containing RNA results in RNA foci throughout the nervous system and may be toxic 8 . Furthermore, these RNA entities undergo repeat-associated non-AUG translation to produce dipeptide repeats-GA, GR, GP, PA, and PR-which form potentially toxic aggregates 8 . The expression of (G4C2) 30+ repeats, independent of changes to expression of the C9orf72 gene product, causes toxicity in multiple model systems [5] [6] [7] . In Drosophila, the expression of (G4C2) 30+ transgenes results in RNA foci formation, dipeptide repeat expression and neurodegenerative effects 5, 6 . Repeat expansions, such as (G4C2) n , have been defined in a number of neurodegenerative diseases. As these repeats tend to be GC-rich, they can form secondary structures (for example, G-quadruplexes) and R-loops that are thought to diminish RNA polymerase II (RNAPII)-driven transcription 7, [9] [10] [11] [12] [13] . Specialized transcriptional machinery may be required to promote the activity of RNAPII through such long repeat expansions 11, 13 . Of note, the DRB-sensitivity-inducing factor (DSIF) complex and the RNA polymerase II associated factor 1 complex (PAF1C) are RNAPII regulators that may be involved, since transcription of GC-rich DNA is sensitive to their loss [14] [15] [16] . DSIF and PAF1C are highly conserved and have non-redundant roles in activating RNAPII during elongation [17] [18] [19] [20] . DSIF is composed of two proteins, Spt4 and Spt5 (SUPT4H and SUPT5H, respectively, in humans) 18 . SUPT4H is implicated as a transcriptional regulator of expanded CAG and G4C2 repeats in disease [21] [22] [23] . PAF1C is composed of five proteins-Paf1, Leo1, CDC73, Ctr9, and Rtf1-and it is unknown whether human PAF1C (hPAF1C) has a role in diseases involving repeat expansions 19, 20 . Downregulation of PAF1C can affect elongation rates of RNAPII, although only a subset of genes are known to require its function for expression [24] [25] [26] . In the nervous system, PAF1C is critical during development, although it remains expressed in mature neurons [27] [28] [29] [30] [31] [32] . Here, using an unbiased large-scale RNA interference (RNAi)-based screen in Drosophila melanogaster expressing toxic (G4C2) 49 , we identified PAF1C components as modifiers of C9orf72-associated disease. Downregulation of PAF1C components disrupted the transcription of G4C2 RNA in both Drosophila and Saccharomyces cerevisiae and resulted in reduced toxicity in Drosophila. Notably, the Drosophila components Paf1 (dPaf1) and dLeo1 appeared selective for the transcription of long, disease-associated repeat transgenes but not short repeats. Depletion of other dPAF1C subunits and dSpt4 affected both long and short repeats. Furthermore, PAF1C was upregulated in response to expression of the expanded repeat in flies, a mouse model, C9
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+ patient-derived cells, and C9 + FTD tissue. Notably, expression of hPAF1 and hLEO1 positively correlated with the expression of repeat-containing C9orf72 transcripts in patient tissue, and hLeo1 bound to C9orf72 chromatin in C9 + cells. These data highlight that hPAF1C is an important transcriptional regulator of expanded G4C2 within C9orf72.
Toxic expanded GGGGCC repeat transcription is mediated by the PAF1 complex in C9orf72-associated FTD ( Supplementary Fig. 1b,c) . Overall, 119 modifiers of (G4C2) 49 toxicity were identified, of which 55 were suppressors and 64 were enhancers (Fig. 1f) .
To define enriched processes, functions, or components within these 119 modifiers, gene ontology (GO) term analyses were performed (see Methods). Enrichment scores (the degree to which a list of genes in a GO term are represented within the modifier list when compared to the total list of genes tested) were plotted for GO terms that were significantly (P value threshold of 10 −3
) represented within the panel of modifiers (Supplementary Fig. 1d ; Supplementary Data). Among the suppressors, there was strong enrichment for genes associated with RNAPII-driven transcription ( Fig. 1g, green ; Supplementary Data), including components of dPAF1C and the dMediator complex 33 . Additional transcription regulators included dELL and dEar of the dSuper elongation complex (dSEC) 16 and dSpt4 of the dDSIF complex. By contrast, enhancers of (G4C2) 49 toxicity varied in GO terms. Genes involved in RNA processing and splicing were identified, with components of the precatalytic spliceosome being the most enriched complex ( Fig. 1h , red; Supplementary Data).
Overall, dPAF1C was the most enriched complex of transcriptional regulators whose knockdown suppressed (G4C2) 49 toxicity.
PAF1C is selective for toxicity from a G4C2-encoding RNA. Expanded G4C2 RNA can produce the dipeptide repeat proteins GR, GA, and GP in the fly [5] [6] [7] [8] . Of these, (GR) 30+ is strongly toxic 34 . As modifiers of (G4C2) 49 toxicity may be acting downstream of GR peptide production, we analyzed the 119 RNAi lines for their ability to modulate (GR) 36 toxicity (Fig. 2a) . GR models express a GR peptide from a non-G4C2 RNA transcript, thus avoiding potential toxicity caused by a G4C2 repeat-bearing RNA 34 . As the PAF1 and DSIF complexes may be of particular interest in repeat-associated disease, dPAF1C and dSpt4 RNAi were rigorously examined for modification of (GR) n toxicity in flies and yeast (see Supplementary  Fig. 2a -c for S. cerevisiae Spt4 (scSpt4) (ref. 23 )). Results did not show consistent or significant effects, indicating that these modifiers have a minimal effect on (GR) n -associated toxicity.
In Drosophila, 48 of the 119 modifiers (40.3%) did not alter (GR) 36 toxicity in the same manner that they altered G4C2 repeat toxicity, suggesting that they modulate the expression of RNA or RNA-derived toxicity ( Fig. 2b ; Supplementary Data). A GO term analysis of these modifiers revealed that suppression by dPAF1C components was selective to the (G4C2) 49 model (Fig. 2c ). By contrast, the dMediator complex and dELL and dEar of dSEC similarly suppressed both (G4C2) 49 and (GR) 36 toxicity in the external eye.
Overall, these data suggest that dPAF1C RNAi suppression of (G4C2) 49 toxicity is the result of effects upstream of toxic GR peptide production. dPAF1C is selective for the G4C2 expansion. Biological connections between (G4C2) 30+ expression and TAR DNA-binding protein 43 (TDP43) pathology have been reported in C9 + FTD and ALS 5, 8 . Thus, we examined the (G4C2) 49 modifiers in a TDP43 model to define G4C2-unique pathways (Fig. 2a) . Expression of hTDP43 in the fly eye causes toxicity 35 . Rigorous assessment of dPAF1C and dSpt4 RNAi showed that they did not significantly affect TDP43 toxicity ( Supplementary Fig. 3a,b) . Overall, 56 out of the 119 (G4C2) 49 modifiers (47.1%) were unique to (G4C2) 49 ( Fig. 2b ; Supplementary Data). A GO term analysis indicated that dPAF1C was again highly enriched, underscoring the specificity of this complex to the expanded G4C2 (Fig. 2d) . By contrast, other RNAPII regulators, such as the dMediator complex and dELL and dEar of dSEC, similarly suppressed (G4C2) 49 or TDP43 toxicity in the external eye (see also ref. 35 ). Furthermore, dPAF1C RNAi did not alter TDP43 protein levels ( Supplementary Fig. 3c ).
Taken together, these data highlight the selectivity of dPAF1C downregulation toward (G4C2) 49 -associated toxicity. dPAF1C downregulation suppresses (G4C2) 49 -induced toxicity in flies. We further examined whether dPAF1C downregulation could affect (G4C2) 49 toxicity in multiple fly tissues. First, we confirmed that the RNAi lines targeting dPAF1C components-dPaf1 (also known as ATMS), dLeo1 (also known as ATU), dCDC73 (also known as HYX), dCtr9, and dRtf1-resulted in significant downregulation of the target gene, while extending reagents to include an independent set of dPAF1C RNAi lines ( Supplementary Fig. 4) .
Consistent with the effects observed in the external eye, coexpression of dPAF1C RNAi with (G4C2) 49 rescued internal tissue loss (Fig. 3a,b) . dPaf1, dLeo1, and dRtf1 RNAi caused ~80% recovery and dCDC73 and dCtr9 RNAi caused ~100% recovery of tissue depth. The following results were obtained: control = 13.4 ± 6.2 μm, dPaf1 = 44.4 ± 4.7 μm, dLeo1 = 47.2 ± 10.8 μm, dCDC73 = 63 ± 6.1 μm, dCtr9 = 69.1 ± 18.0 μm, and dRtf1 = 41.8 ± 12.7 μm. This finding indicates that dPAF1C depletion is markedly effective in mitigating (G4C2) 49 toxicity in the eye. Downregulating dPAF1C components did not affect the external or internal eye on their own (Fig. 3c,d ). The second set of dPAf1C RNAi lines also suppressed (G4C2) 49 toxicity, while not affecting the normal fly eye, verifying that suppression is indeed the result of targeting dPAF1C ( Supplementary Fig. 5a,b) . To confirm the effect on G4C2-induced toxicity, an independent (G4C2) 30+ disease fly model was examined for interactions with dPAF1C (see Methods). This model contains 114 base pairs of the intronic sequence found upstream of the G4C2 repeat in patients (termed the leader sequence (LDS)). Again, dPAF1C RNAi suppressed toxicity caused by LDS-(G4C2) 44 GR-GFP expression within the fly optic system (Supplementary Fig. 5c ).
To examine the effects of downregulating dPAF1C components in the nervous system, we expressed the (G4C2) 49 transgene using a drug-inducible neuronal GAL4 driver, ElavGS. First, we assessed the climbing ability of animals with adult-onset expression. At 14 days, only 41% of (G4C2) 49 -expressing animals were able to climb 4 cm up the wall of a vial within 20 s (Fig. 3e) . dPAF1C RNAi significantly suppressed this effect, causing climbing abilities to be mRNA 5´-UTR binding (GO:0048027) (G4C2) 49 49 No start codons present Optic system driver: GMR-GAL4 Control d (G4C2) 8 (G4C2) 29 (G4C2) 49 Mean length (± 5%) 2. 49 toxicity in the fly eye when downregulated. a, UAS-(G4C2) n transgenes were designed to express a pure repeat. b, PCR experiments were used to quantify of the number of repeats in individual UAS-G4C2 transgenic fly lines. Shown are individual data points with the mean from two experiments (30 flies per experiment). c, RNA expression of UAS-(G4C2) n transgenes using HS-GAL4 were compared by northern blots. Statistics: ANOVA with Tukey's correction, NS, not significant (P > 0.05). Shown are individual data points with mean ± s.e.m. of biological triplicates (n = 30 flies) from three independent experiments. d, Expression of UAS-(G4C2) n transgenes in the fly eye compared with controls: (G4C2) 8 had no effect, (G4C2) 29 caused mild disruptions in 80% of animals, (G4C2) 49 caused strong degeneration. Shown are data from one experiment; data were reproduced in three or more independent experiments. Double-headed arrows indicate internal tissue depth arrowhead indicates lost tissue. e, Left: RNAi was co-expressed with (G4C2) 49 (III) within the fly optic system. Effects of RNAi were recorded as suppressors (reduced degeneration) or enhancers (increased degeneration). Right: representative images of the effects. Hits were independently tested three or more times to confirm reproducibility (>5 flies examined per cross). f, A total of 119 modifiers were identified. Control experiments excluded 231 RNAi lines with nonspecific effects. g, h, GO analyses revealed terms enriched in suppressors (55 out of 3,582 genes) or enhancers (64 out of 3,582 genes). Plotted terms are those with significant (P ≤ 10
) enrichment scores of >3.00. For d, e, scale bars, 100 μm (external eye), 25 μm (internal eye). Additional details for this figure and subsequent figures are provided in Supplementary Fig. 1 (extended screen data), Supplementary Data (all screen results), Supplementary Table 1 (detailed sampling, reproducibility, and statistics) and the Methods. maintained at 92-96%. Suppression was again seen when using the second set of dPAF1C RNAi lines ( Supplementary Fig. 5d ).
Next, we analyzed animals for age-dependent vacuole formation in the fly brain, an indicator of neurodegeneration. (G4C2) 49 expression in the adult-fly nervous system caused large vacuoles throughout the brain at 28 days. dCDC73, dCtr9, and dRtf1 RNAi significantly reduced both vacuole size and number. The mean degeneration score (3.4 ± 0.5) was reduced to 2.10 ± 0.6 (dCDC73 RNAi), 2.38 ± 0.5 (dCtr9 RNAi), and 1.78 ± 0.8 (dRtf1 RNAi), with the normal brain being 1.1 ± 0.4 ( Fig. 3f; Supplementary Fig. 6 ). Furthermore, the strong suppressor dCDC73 increased adult survival of (G4C2) 49 -expressing animals, with 50% survival extended by 24 h and the end point extended by 72 h (Fig. 3g) . RNAi targeting other dPAF1C components showed reduced lifespan in control flies, making it inaccurate to evaluate their activity as suppressors of (G4C2) 49 lifespan (Supplementary Fig. 7a ). We further rigorously ruled out any possible genetic background effects of the RNAi lines within the context of (G4C2) 49 expression (Supplementary Fig. 8) .
Together, our data show that dPAF1C plays an important role in (G4C2) 49 -induced toxicity in disease-relevant tissues in the fly.
PAF1C mediates the expression of expanded G4C2 in fly and yeast. Given that PAF1C regulates RNAPII elongation and is important for transcription of GC-rich DNA 15, 19, 20 , we hypothesized that PAF1C may be important for the successful transcription of long G4C2 repeats.
We first determined whether downregulation of dPAF1C components-dPaf1, dLeo1, dCDC73, dCtr9, and dRtf1-affected the Overlap between (G4C2) 49 , (GR) 36 , and TDP43 fly eye modification Modifiers of (G4C2) 49 but not (GR) 36 toxicity (G4C2) 49 suppessors TDP43 and (G4C2) 49 (G4C2) 49 enhancers (GR) 36 and (G4C2) 49 All three
Transcription
Chromatin organization 36 or TDP43 toxicity in Drosophila. a, The 119 (G4C2) 49 modifiers were analyzed in (GR) 36 and TDP43 models to determine whether they could act on GR dipeptide toxicity or had overlapping effects on TDP43 toxicity. All were independently tested three or more times to confirm reproducibility of the results (>5 flies examined per cross). Scale bars, 100 μm. b, Of the 119 modifiers of (G4C2) 49 toxicity, 71 (59.7%) similarly modified (GR) 36 , suggesting that they may be acting on toxic dipeptide repeats. A total of 63 (52.9%) modifiers similarly affected TDP43 toxicity, arguing that there is overlap between these disease models. c, GO analyses revealed terms enriched in the modifiers that did not similarly alter (GR) 36 toxicity (48 of 3,582 genes), revealing those acting selectively on the (G4C2) 49 RNA model. d, GO analyses revealed terms enriched in the modifiers that did not similarly alter TDP43 toxicity (56 of 3,582 genes), revealing those specific to the expanded G4C2 repeat in C9 + FTD and ALS. For c and d, the plotted GO terms were those with significant (P ≤ 10
) enrichment scores of >3.00.
UAS-RNAi ElavGS > (G4C2) 49 (14 days) **** (G4C2) 49 RNAi mitigated vacuole formation (arrowheads) in the brain with ElavGS-driven expression of (G4C2) 49 . For quantification, a vacuole severity scoring system was developed, whereby 0 = no vacuoles and 4 = medium-large, frequent (>5) vacuoles (see Supplementary Fig. 6a ). The numbers of flies tested were as follows: (G4C2) 0 = 9; (G4C2) 49 : control = 10, dPaf1 = 10, dLeo1 = 7, dCDC73 = 10, dCtr9 = 8 and dRtf1 = 9. Scale bars, 50 μm. g, Knockdown of dCDC73 in adult flies ubiquitously expressing (G4C2) 49 results in lifespan extension. The numbers of flies tested were as follows: control = 198 and dCDC73 = 197. For b, d and f, each data point represents one animal. Statistics are as follows: a-f, ANOVA with Tukey's correction; g, log-rank; ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05. Shown on graphs are individual data points with mean ± s.d. of data from one experiment; all experiments were repeated twice with similar results obtained. (G4C2) 29 (G4C2) 49 ** **** * ** ** * (G4C2) 8 (G4C2) 29 (G4C2) 49 *** *** *** **** NS NS NS NS * * **** **** **** ** **** ******** * **** **** **** **** **** 44 GR-GFP levels TDP43 NS **** **** **** RNAi lines in the adult brain using a drug-inducible, neuronal driver (ElavGS, 16 d old). Transgene expression levels in heads measured by qPCR. dPaf1 and dLeo1 RNAi did not affect RNA levels of (G4C2) 8 and (G4C2) 29 , but they significantly reduced (G4C2) 49 expression. dSpt4, dCDC73, dCtr9, and dRtf1 RNAi altered expression of all (G4C2) n transgenes. Shown are individual data points with mean ± s.e.m. of three biological replicates (n = 25 flies per replicate) from two or three independent experiments. b, dPAF1C RNAi did not alter TDP43 (ElavGS, 16 d old, heads) RNA levels by qPCR. Shown are individual data points with mean ± s.e.m. of three biological replicates (n = 25 flies per replicate) from two independent experiments. c, Downregulation of dPAF1C components reduces the GR-GFP signal in LDS-(G4C2) 44 GR-GFP animals. Quantification of total GFP fluorescence relative to control animals. The numbers of flies tested were as follows: control = 8, dPaf1 = 7, dLeo1 = 4, dCDC73 = 6, dCtr9 = 6 and dRtf1 = 6. Each data point represents one eye of one animal. Shown are data from one experiment, with data reproduced in two independent experiments. Scale bars, 100 μm. d, Effects of deleting scCDC73 (cdc73Δ) or scLeo1 (leo1Δ) in S. cerevisiae on RNA levels from transgenes assessed by qPCR. Transgenes included eYFP (control), sense (G4C2) 66 (disease) and antisense (G2C4) 66 (disease). Shown are individual data points with mean ± s.d. of biological duplicates from two independent experiments. WT, wild type. Statistics are as follows: ANOVA with Tukey's correction; ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05. amount of RNA produced from expanded (G4C2) 49 transgenes in the fly nervous system, using dSpt4 RNAi as a positive control 23 ( Fig. 4a,  red) . dPAF1C RNAi caused the following significant reductions in (G4C2) 49 RNA: dPaf1 = 41 ± 8% reduction, dLeo1 = 54 ± 4% reduction, dCDC73 = 57 ± 5% reduction, dCtr9 = 62 ± 6% reduction, and dRtf1 = 62 ± 5% reduction. These values were similar to dSpt4 RNAi, which caused 52 ± 5% reduction (see also ref. 23 ). This effect was consistent in a second (G4C2) 49 fly line ( Supplementary Fig. 9a) .
We evaluated the specificity of dPAF1C alterations on expanded, disease-associated (G4C2) 49 RNA by assessing expression from a short (G4C2) 8 and an intermediate-length (G4C2) 29 repeat. Unexpectedly, dPaf1 and dLeo1 were selective for expanded (G4C2) 49 as these RNAi did not significantly reduce expression from the shorter repeat transgenes not associated with FTD and ALS (Fig. 4a, black and green) . By contrast, dSpt4, dCDC73, dCtr9, and dRtf1 RNAi caused significant reductions (>30%) in expression from (G4C2) 8 and (G4C2) 29 , similar to effects on the (G4C2) 49 transgene. Statistical comparisons between each (G4C2) n transcript levels with individual RNAi (Fig. 4a, upper panel) confirmed that dPaf1 and dLeo1 RNAi did not show significant differences between the expression level of (G4C2) 8 and (G4C2) 29 but caused a significant drop between (G4C2) <30 and (G4C2) 49 RNA levels. By contrast, dSpt4 RNAi and other dPAF1C RNAi had statistically similar decreases in RNA levels among short and expanded G4C2 repeat lengths. These findings suggest that of the dPAF1C components, dPaf1 and dLeo1 appear to be of special importance for the expression of longer, disease-associated repeat expansions in the fly. We further confirmed that the reduced expression was specific to the G4C2 construct by examining the expression of an alternative disease transgene, TDP43. TDP43 transcript levels were not affected by dPAF1C RNAi in the fly brain, consistent with the protein data ( Fig. 4b; Supplementary Fig. 3c ).
As (G4C2) 30+ RNA can produce a toxic GR dipeptide, we next tested whether reduced expression of dPAF1C could alter GR production in the LDS-(G4C2) 44 GR-GFP fly model (Fig. 4c) . The green fluorescent protein (GFP) tag in the GR reading frame enables fluorescence imaging and quantitation of GR levels in eyes with Gmr-GAL4. Congruent with the RNA data, dPAF1C RNAi caused the following significant downregulation of GR-GFP: dPaf1 = 40 ± 3% reduction, dLeo1 = 42 ± 2% reduction, dCDC73 = 56 ± 1% reduction, dCtr9 = 50 ± 3% reduction, and dRtf1 = 51 ± 2% reduction.
These findings were then extended to yeast to assess whether scPAF1C could regulate the expression of expanded G4C2 in another model system. Transgenes were expressed from a galactoseinducible promoter. scLeo1 (leo1Δ) or scCDC73 (cdc73Δ) deletion had mild or no effect on expression from a control enhanced yellow fluorescent protein (eYFP) transgene (Fig. 4d, black) . Deletion of other scPAF1C components led to growth defects and/or significantly repressed the expression of control eYFP so could not be assessed (data not shown). Interestingly, RNA levels from an expanded (G4C2) 66 transgene were significantly decreased by leo1Δ or cdc73Δ, with 40 ± 14% and 38 ± 2.5% reduction, respectively (Fig. 4d, red) . Furthermore, as the hexanucleotide repeat in patients with C9
+ FTD-ALS can be transcribed bidirectionally 8 , we determined whether scPAF1C mutants could also regulate expression from an antisense (G2C4)66 transgene. Notably, leo1Δ and cdc73Δ had an even stronger effect on expression from this transgene, with leo1Δ showing a significantly stronger effect than cdc73Δ (77 ± 4% and 52 ± 11% reduction, respectively) (Fig. 4d, orange) . These data confirm that PAF1C downregulation impairs the expression of expanded G4C2 repeats in an independent model system, and extend these data to expanded antisense G2C4 repeats.
Effects of PAF1C RNAi could be the result of co-regulation of PAF1C components-Paf1, Leo1, CDC73, Ctr9, and Rtf1-with each other and/or Spt4. To examine this possibility, we expressed dPaf1, dLeo1, or dCDC73 RNAi in adult flies using the drug-inducible ubiquitous driver DaGS. Quantitative PCR (qPCR) was used to determine changes in expression from dPAF1C components not targeted by the RNAi or dSpt4 (Supplementary Fig. 7b ). Data indicated that depleting these dPAF1C components did not alter the expression of dSpt4 or alternative dPAF1C components, with a potential, weak interaction between dCDC73 RNAi and dCtr9 levels. Furthermore, we confirmed that downregulating PAF1C in flies and yeast did not alter general RNAPII transcription by looking at RNA expression from endogenous housekeeping genes 19, 20, [24] [25] [26] ( Supplementary Fig. 9b,c) .
These data show that PAF1C mediates the transcription of expanded G4C2 and G2C4. Furthermore, data from the fly experiments suggest that dPaf1 and dLeo1 confer repeat-length specificity to the transcriptional machinery, promoting RNAPII-driven transcription of disease-associated (G4C2) 30+ repeat expansions.
PAF1C is upregulated in response to expanded G4C2. Given the important role that dPAF1C is playing in (G4C2) 49 -expressing animals, we considered that the complex may be dysregulated in C9 + situations. Thus, we examined the expression of endogenous dPAF1C components-dPaf1, dLeo1, dCDC73, dCtr9, and dRtf1-in animals expressing (G4C2) 49 in the adult-fly nervous system (ElavGS, 16 days). Surprisingly, all components were upregulated, as assessed by qPCR (Fig. 5a) . Specifically, dPaf1 = 69 ± 10% upregulation, dLeo1 = 58 ± 13% upregulation, dCDC73 = 71 ± 17%upreg-ulation, dCtr9 = 49 ± 12% upregulation, and dRtf1 = 64 ± 5% upregulation. This effect did not occur in response to short (G4C2) 8 repeat expression. Furthermore, dPAF1C upregulation appeared selective for G4C2-associated disease, as dPAF1C components were not upregulated in TDP43-expressing animals but instead were downregulated (Fig. 5b) .
To determine whether this same response to expression of the expanded G4C2 repeat occurred in mammals, protein levels of mouse Leo1 (mLeo1) were measured in cortical tissue from mice expressing (G4C2) 2 or (G4C2) 149 (Fig. 5c ). Transgenes were expressed using an AAV2/9 vector, which predominantly transduces into neurons (see Methods). At 3 months post-injection, no significant differences in mLeo1 were detected between cohorts. However, at 6 months, a significant upregulation (by 30 ± 8%) in mLeo1 was observed in (G4C2) 149 animals compared with (G4C2) 2 animals.
hPAF1 is upregulated in C9
+ patient-derived cells. Our data from flies and mice indicated that PAF1C is upregulated in response to expression of an expanded G4C2 repeat in the brain. To better understand this effect in C9 + disease, we extended our studies to patient-derived cells. Protein expression levels of four of the hPAF1C components-hPAF1, hLEO1, hCDC73, and hRTF1-were assessed by western immunoblotting in undifferentiated induced pluripotent stem (iPS) cells (Fig. 6a and Supplementary  Fig. 10a ). The mean expression from three C9 + patient-derived cell lines was compared to three control cell lines. Notably, hPAF1 and hRTF1 were significantly upregulated by 46 ± 14% and 54 ± 14%, respectively, in C9 + derived iPS cells.
hLeo1 binds C9orf72 within the genome. Thus far, our data from flies, mice, and C9 + patient-derived cells have shown that levels of select PAF1C components are modulated in response to expression of the repeat. Furthermore, PAF1C is important for the expression of expanded G4C2 in flies and yeast. Therefore, we considered that hPAF1C may be recruited and bound to C9orf72 within the genome of patient-derived cells.
To assess this, chromatin immunoprecipitation (ChIP) studies were performed. Four, independent C9 + -derived fibroblast lines ( Supplementary Fig. 10a ) were assayed using a hLeo1-specific antibody (Fig. 6b) . Importantly, Leo1 forms a heterodimer with Paf1 within PAF1C when bound to RNAPII 36, 37 . After pull-down, the presence of the C9orf72 gene or an intergenic (noncoding) sequence was assessed by qPCR, and the mean enrichment of the four lines was calculated. Primers used to detect chromatin fragments from the C9orf72 gene targeted the intronic region immediately 3′ of the repeat expansion. Notably, there was a 4.9 ± 1.8-fold enrichment of the C9orf72 sequence over the intergenic sequence and IgG controls with hLeo1 ChIP, indicating that hLeo1, of the Paf1-Leo1 heterodimer, was bound to the C9orf72 gene in patient-derived C9 + cells. Overall, these data support that hLeo1 binds the C9orf72 gene and that it is bound through the repeat.
hPAF1 and hLEO1 are upregulated in C9 + FTD and FTD-ALS. Our data from multiple model systems indicated that PAF1C is important for expression of the expanded G4C2 and that PAF1C is upregulated in response to expression of the repeat. To better understand the role of hPAF1C in human disease, we extended our studies to tissue samples from patients with FTD-ALS.
RNA was extracted from frontal cortex tissue of patients with C9
-disease (n = 56) or control participants with no disease (n = 27), and the levels of hPAF1 and hLEO1 expression were assessed by qPCR ( Fig. 6c; Supplementary Fig. 10b ). In patients diagnosed with FTD (cortical disease), hPAF1 and hLEO1 were significantly upregulated only when the repeat expansion was present. hPAF1 was upregulated by 39% versus healthy controls and by 28% versus C9 -FTD, whereas hLEO1 was upregulated by 23% versus healthy controls and by 25% versus C9 -FTD. Interestingly, in the frontal cortex of C9 + ALS cases (motor neuron disease), neither hPAF1 nor hLEO1 was upregulated, independent of the presence of the G4C2 repeat expansion. Patients showing symptoms of both FTD and ALS fell between FTD-only and ALS-only, with C9 + FTD-ALS cases showing a relatively weaker upregulation of hPAF1 and hLEO1 compared to healthy controls (28% and 22%, respectively). In contrast to hPAF1 and hLEO1, hCDC73 did not show altered expression in C9 + FTD (Supplementary Fig. 10c ), supporting the data obtained from Drosophila and patient-derived cells indicating that Paf1 and Leo1 may play a unique role over other components.
Upregulation of hPAF1 and hLEO1 in C9 + FTD is congruent with the data in flies, mice, and iPS cells. Notably, in cortical tissue, this upregulation was unique to patients with C9
+ FTD compared with patients with C9
+ ALS (who lack cortical diagnosis); we note that . Whole head analysis showed no upregulation of PAF1C components. Shown are individual data points with mean ± s.e.m. of biological triplicates (n = 25 flies per replicate) from two independent experiments. c, Mouse endogenous mLeo1 protein levels measured in cortical tissue by western immunoblotting using lysates from mice injected intracerebroventricularly with AAV2/9-(G4C2) 2 or -(G4C2) 149 at postnatal day 0. mLeo1 is upregulated by 6 months in response to expression of expanded (G4C2) 149 . Differences in expression are likely underestimated, as protein was extracted from total cortical tissue and transgenes were expressed using AAV2/9, which predominantly transduces neurons. At 3-months, 6 animals were used for (G4C2) 2 and 6 for (G4C2) 149 . At 6-months, 6 animals were used for (G4C2) 2 and 7 animals for (G4C2) 149 . Shown are individual data points (each representing one animal) with mean ± s.e.m. Data were reproduced in two independent experiments. Statistics are as follows: a, ANOVA with Tukey's correction; b, c, unpaired two-tailed Student's t-test; ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05. See Supplementary Fig. 11 for uncropped western blot images for this and subsequent figures. disease duration could contribute as this differed between cohorts ( Supplementary Fig. 10b ).
Expression of hPAF1 and hLEO1 positively correlates with repeat-containing C9orf72 transcripts. As Paf1 and Leo1 activity was important for the expression of the expanded G4C2 repeat in flies and yeast, and hLEO1 is bound to C9orf72 in C9 + cells, we considered that hPAF1 and hLEO1 upregulation in C9 + FTD may positively correlate with the expression of C9orf72 transcripts containing the repeat.
To examine this, Spearman r correlations were performed between transcript levels of hPAF1 and hLEO1 versus C9orf72 pre-mRNA (Fig. 6d) . Results showed strong (r > 0.3) and significant (P < 0.0005) positive correlations between transcripts in C9 + FTD cases. For hPAF1 versus C9orf72, r = 0.74 with a 95% confidence interval of 0.5-0.9. For hLEO1 versus C9orf72, r = 0.63 with a 95% confidence interval of 0.3-0.8. No correlations were observed in C9 -FTD cases or healthy controls, supporting that this effect is in response to the presence of the repeat expansion. Furthermore, no correlations between hCDC73 transcripts and C9orf72 pre-mRNA were observed, arguing that this effect is unique to hPAF1 and hLEO1 ( Supplementary Fig. 10d ). No correlations were observed in C9 + ALS cases ( Supplementary Fig. 10e ). Altogether, data from multiple models and FTD cortical tissue indicate that PAF1C regulates the expression of expanded G4C2 repeats within C9orf72 in C9 + situations.
Discussion
An unbiased RNAi-based screen in Drosophila covering ~4,000 genes revealed PAF1C as a C9orf72 disease modifier. Downregulation of dPAF1C components-dPaf1, dLeo1, dCDC73, dCtr9, and dRtf1-selectively suppressed (G4C2) 49 toxicity in multiple fly tissues. Mechanistically, dPAF1C suppression was associated with reduced RNA and GR dipeptide production from expanded (G4C2) n transgenes. In particular, depletion of dPaf1 and dLeo1, which form a heterodimer 36, 37 , in the fly nervous system selectively reduced the expression of long, toxic (G4C2) 49 repeats versus shorter, nontoxic repeats. Moreover, scLeo1 and scCDC73 deletion in yeast reduced RNA production from sense (G4C2) 66 and antisense (G2C4) 66 transgenes. Additional investigations into dPAF1C in Drosophila revealed that endogenous dPAF1C was upregulated following expression of expanded, toxic (G4C2) 30+ in neurons. This was not the result of toxicity or stress, as upregulation was selective to (G4C2) 30+ versus a non-G4C2 disease transgene, TDP43. Notably, mLeo1 was also upregulated in the brain of mice expressing (G4C2) 149 , while hPAF1 and hRTF1 were upregulated in C9 + -derived iPS cells. Furthermore, we provide evidence that hPAF1C binds C9orf72, with ChIP for hLEO1 (of the PAF1-LEO1 heterodimer) in C9 + cells. Using human postmortem cortical tissue, we further found that hPAF1 and hLEO1 RNA levels were upregulated in patients with C9 + FTD. This upregulation positively correlated with the expression of the repeatcontaining C9orf72 transcripts. Overall, these data from flies, yeast, mice, C9 + patient-derived cells, and postmortem patient tissue support a mechanistic link between PAF1C activity, expression of the G4C2 repeat within C9orf72 and C9 + disease. A total of 119 modifiers of (G4C2) 49 toxicity were identified in our screen (Fig. 1) . Remarkably, gene ontology (GO) term analyses of the 55 suppressors showed significant enrichment for RNAPII transcriptional regulators, including dPAF1C, the dMediator complex, dELL and dEar of the dSEC, and dSpt4 of the dDSIF complex. Not all transcription-related genes tested in the screen modified (G4C2) 49 toxicity (examples include dCDK9, dCnot4 and dTFIIS), arguing that the complexes identified are unique (see Supplementary Data). Although we focused on dPAF1C, the other RNAPII regulators that modify G4C2 toxicity may also be important in disease [5] [6] [7] [8] . Among the 64 enhancers of (G4C2) 49 toxicity, RNA processing and splicing factors were prominent. Curiously, the majority of these enhancers similarly modulate (GR) 36 toxicity (Fig. 2) . These data are consistent with reports of RNA dysregulation and splicing deficits in C9 + FTD-ALS, while also suggesting that disruptions in RNA metabolism may result from toxic GR [5] [6] [7] [8] . RNAPII-driven transcription across GC-rich DNA is hypothesized to be problematic due to the propensity of such DNA and RNA to form secondary structures, such as R-loops and G-quadruplexes 7, [9] [10] [11] [12] [13] . Given this, the activity of multiple elongation factors may be required for efficient transcription through expansions such as (G4C2) 30+ (refs. 11,13 ). Spt4 was previously implicated as a transcriptional regulator of CAG and G4C2 repeat expansions [21] [22] [23] . Our data indicate that PAF1C regulates the expression of G4C2 repeats in FTD and ALS (Fig. 4) . dPaf1 and dLeo1 of dPAF1C seem particularly important for RNAPII transcription of expanded G4C2, as loss of these two components selectively reduced the expression of a disease-relevant (G4C2) 49 transgene in flies. While this could be the result of the level of knockdown, it is compelling that Paf1 and Leo1 form a heterodimer that is important for PAF1C activation of elongating RNAPII 25, [36] [37] [38] [39] . Furthermore, Paf1 is consistently upregulated in C9 + patientderived cells and tissue compared with other components, and upregulation positively correlated with the expression of repeatcontaining transcripts in patient tissue ( Fig. 6c,d ; Supplementary  Fig. 10 ). Overall, these data argue that PAF1 and LEO1 are mechanistically special in C9 + disease. In contrast to dPaf1 and dLeo1, dSpt4 showed similar effects on different G4C2 repeat lengths in flies (Fig. 4) . Differences in how Spt4 and the loss of Paf1 and Leo1 affect expanded G4C2 expression may be due to their distinct roles during transcription [17] [18] [19] [20] . Evidence suggests that Spt4 primarily acts during the transition of RNAPII from poised to elongation or during transcription termination 17, 25, 26 . By contrast, Paf1 and Leo1 seem to act primarily during elongation 17, 25, 26, 38, 40 . Notably, DSIF (composed of Spt4 and Spt5) and PAF1C may interact. In yeast, scDSIF recruits scPAF1C via the scRtf1 subunit during the transition of RNAPII from initiation to elongation 41 . However, in higher organisms, including Drosophila, the dependence of PAF1C on DSIF for recruitment to elongating RNAPII is less clear. Rtf1 is less tightly associated with other PAF1C components, while recent work has shown that PAF1C recruitment can be DSIF-independent in mammals [42] [43] [44] [45] [46] . Furthermore, Leo1 of PAF1C directly interacts with elongating RNAPII 37 and the C9orf72 gene (Fig. 6b) . Together, these data suggest that PAF1C plays a unique role in transcription elongation across the G4C2 repeat expansion.
FTD and ALS represent the extremes of a continuous disease spectrum. It remains unclear how one patient presents with FTD and another with ALS or combined FTD-ALS. Among many factors, unique genetic backgrounds of individuals may contribute to specific presentation 3, 4 . For example, ATXN2 and TMEM106B have been suggested as disease modifiers underlying the different diagnoses 3, 4 . Curiously, we observed selective upregulation of hPAF1 and hLEO1 in the frontal cortex of C9 + FTD disease but not C9 + ALS (Fig. 6c) . Importantly, the frontal cortex is thought to be a primary brain region resulting in FTD-associated symptoms 47, 48 . Stage of disease progression could also contribute to our results and should be considered (Supplementary Fig. 10b ). Analyses of hPAF1 and hLEO1 expression in motor neurons from patients with ALS will define whether PAF1C plays a tissue-specific role. Based on current data, it is tempting to hypothesize that cortical modulation of PAF1 or LEO1 in response to the repeat may be among several mechanisms contributing to the spectrum of disease phenotypes in C9orf72-associated disorders.
PAF1C may be an attractive therapeutic candidate for C9 + FTD. In yeast, scPAF1C has been reported to be nonessential 19, 20 . In flies, dLeo1 is not essential to obtain viable adults 49 . In mice, mPAF1
+/-heterozygosity yields no obvious abnormalities, while mPaf1 -/-and mLeo1 -/-animals show pre-weaning lethality 50 . Other components of mPAF1C follow this same trend, with heterozygous mice showing no or few effects 50 . While SUPT4H (human SPT4; nonessential in yeast) was previously proposed as a potential therapeutic target in C9 + FTD-ALS 23 , it may have more critical organismal functions than PAF1C in higher organisms. Supt4a +/-(murine Spt4) heterozygous mice are viable but show a number of abnormalities, and Supt4a -/-mice are embryonic lethal 50 . These investigations do not consider effects of PAF1C or Spt4 loss in a tissue-or age-specific manner, arguing that further analyses are required. Altogether, we hypothesize that specific components of PAF1C, such as PAF1 or LEO1, may represent a potential therapeutic target for C9orf72-associated disease.
This study presents evidence that PAF1C is an important player in C9orf72-associated disease, particularly in C9 + FTD. Further investigations into PAF1C may define the mechanisms by which it becomes upregulated-potentially in a tissue-specific and/or disease-progressive manner-and its impact on other neurodegenerative situations that result from the aberrant expression of repeat expansions.
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Methods
Nomenclature. For clarity, d for Drosophila melanogaster, h for Homo sapiens, m for Mus musculus, or sc for S. cerevisiae was added in front of gene and protein symbols when discussing endogenous PAF1C components in individual species.
Patient sample consent and approvals. Participants or authorized family members provided written informed consent before gathering information. Post-consent, autopsies were performed postmortem. Protocols were approved by the Mayo Clinic Institutional Review Board and Ethics Committee.
Clinical, genetic, and pathological assessments. Patients were diagnosed with FTD and/or ALS by trained neurologists after reviewing neurological and pathological information (Supplementary Fig. 10b ). Repeat-primed PCR was used to determine the presence or absence of a C9orf72 repeat expansion 1 .
Mouse model and approvals. All mouse procedures were performed in agreement with the National Institutes of Health Guide for the Care and Use of Experimental Animals, approved by the Mayo Clinic Institutional Animal Care and Use Committee. The G4C2 mouse model (C57BL/6J, male mice) was established previously 51 .
Drosophila work and disease models. Stocks were maintained on standard cornmeal-molasses medium. Supplementary Table 2 and Supplementary Data provide details on the fly lines used. For all experiments, multiple w -and w + controls were analyzed in parallel and showed similar results. Supplementary Table 3 provides details on the controls.
Fly RNAi efficacy. All control and PAF1C RNAi lines are defined in Supplementary  Table 2 . RNAi efficacy was determined using Da-GAL4 (larvae) or DaGS (adult animals), as previously described 23, 52 . For Paf1 RNAi, larvae were collected using 20% sucrose solution. For Leo1 RNAi, wandering third instar larvae were collected.
Characterization of (G4C2) n fly models. All G4C2 fly models. Transgenes were inserted into pUAST vectors and randomly inserted into w 1118 fly genomes. The original G4C2 model is detailed in Fig. 1a , and previously described 23, 53, 54 . The LDS-G4C2 model includes a 5′ leader sequence (LDS; 114-bp sequence found upstream of the repeat in intron 1 of C9orf72 in patients) and a 3′-GFP tag in the GR reading frame 55 .
Repeat-length determination. Inserted transgenes were amplified from genomic DNA using construct-specific primers that flanked the repeat (Supplementary  Table 4 ) by PCR using a KAPA HiFi HotStart kit (Kappa, no. KK2501), with GC buffer, 1 M betaine, and 5% dimethylsulfoxide. PCR products lengths were analyzed using 1.5% agarose/TAE gel and a Bioanalyzer. The repeat number was calculated from the PCR product length (subtracting 5′ and 3′ non-G4C2 flanking sequences). Control w 1118 animals were included and showed no signal.
RNA expression for the original UAS-G4C2 model. UAS-G4C2 transgenes were expressed using HS-GAL4 for 30 min at 37 °C. RNA was extracted 3 h post-HS induction and analyzed by northern blotting, probing for the SV40 terminal sequence, as previously described 56 . Control w 1118 animals were included and showed no signal.
RNAi external fly eye screen. UAS-RNAi lines developed by the Transgenic RNAi Project 57, 58 were purchased through the Bloomington Drosophila Stock Center (BDSC). All available Valium 20 UAS-short hairpin RNA lines targeting unique genes were used for screening (detailed in Supplementary Data). When multiple Valium 20 fly lines targeting a single gene were available, one line was randomly selected for screening. Additional UAS-RNAi lines targeting dPaf1 and dLeo1 were obtained from the Vienna Drosophila Resource Center (VDRC) 59 .
External eye screening and imaging. UAS-RNAi males were crossed to recombinant females to produce UAS-(G4C2) 49 , Gmr-GAL4 (III) (grown at 25 °C). Multiple controls were setup with every experiment to account for natural variability in (G4C2) 49 toxicity, including UAS-Luc RNAi (BDSC, no. 31603) and w
1118
; UASDsRed. The external eye phenotype for more than five 1-2-day-old progeny was observed using a standard dissection microscope. Any changes to the ommatidial organization, eye size, pigmentation, and ability to eclose from pupae were noted. Resulting phenotypes were categorized into one of the following six groups: suppressors, mild suppressors, no effect, mild enhancers, enhancers, and lethal enhancers ( Supplementary Fig. 1a ). Animals expressing RNAi that altered (G4C2) 49 toxicity were imaged using a Leica Apo16 microscope 35, [60] [61] [62] . Researchers were blinded to the RNAi targets during screening. Modifiers of (G4C2) 49 toxicity were further assessed in Gmr-GAL4 > UAS-(GR) 36 (ref. 34 ) or UAS-TDP43 (refs. 60, 61 ) animals. Modifier crosses were repeated three or more times independently to confirm the reproducibility of results.
Control experiments defining nonspecific RNAi. To determine whether RNAi caused toxicity in control scenarios, UAS-RNAi lines that enhanced (G4C2) 49 toxicity were tested for effects in lines expressing short repeats, Gmr-GAL4 > (G4C2) 6 or (G4C2) 8 , and with Gmr-GAL4 only. UAS-RNAi lines were analyzed for effects on the GAL4/UAS system using UAS-β-galactosidase western immunoblots, as previously described 23, 35, 54, 62 .
Gene ontology enrichment analysis. GO term enrichment analyses were done using GOrilla software, with a P value threshold of 10 −3 (refs. [63] [64] [65] ). All genes included in the RNAi library, excluding nonspecific RNAi, were set as the background. GO terms with enrichment scores < 3.0 were excluded as these associated with umbrella categories. For final figures, redundant GO terms were excluded using Revigo, prioritizing terms with high enrichment scores 65, 66 . A full list of obtained GO terms can be found in the Supplementary Data.
Internal eye and vacuole formation. Heads were paraffin embedded and sectioned at 8 μm, as previously described 23, 35, 62, 67 . Quantification of internal eye was done by measuring the depth of the retinal tissue at a consistent level of the brain (when the optic chiasm, antennal lobe, and ventrolateral protocerebrum were present). Retinal tissue depth was measured at the point of the optic chiasm. Animals with collapsed eyes were excluded. Quantification of vacuole formation was done using a scoring schematic (Supplementary Fig. 6a ). The whole brain was reviewed for scoring, with researchers blinded to the genotype. Representative images were taken at a consistent level of the brain as described for retinal tissue analyses.
Drug-inducible expression using geneswitch-(GS-) GAL4 drivers. Adult flies (0-2 days old) were collected and aged for 24-48 h before transfer to 0.04 mg RU486-containing food (made by pipetting 100 μl of 4 mg ml -1 RU486 in 100% ethanol onto standard food and incubating at room temperature for 1-2 days with slow rotation). Flies were transferred to fresh RU486-containing food every 2 days.
Lifespan and negative geotaxis (climbing).
Lifespan and climbing assays were performed as previously described but with minor changes 23, 62 . Assays were done at 24 °C. For the climbing assay, flies were tapped to the bottom of an empty vial and immediately video recorded. Each vial was subjected to three consecutive trials with a 20-30-min recovery between trials. For analysis, the number of flies in a vial that crossed a 4-cm line after 15 or 20 s post-tapping were counted. The mean value from the three trials per vial was used to account for technical variability.
Western immunoblots. Fly lysates and reagents.
For assays involving Gmr-GAL4 1-to 3-day-old animals were used. Triplicate samples of 5-10 heads per genotype were collected. For assays involving DaGS, animals were maintained on 0.04 mg RU486-containing food for 10 d, and triplicate samples of 5 animals per genotype were collected. Fly tissue was homogenized in 1× NuPAGE LDS sample buffer plus 2.5% β-mercaptoethanol using disposable pellet pestle tissue grinders (Kimble Chase, no. 749520-0000) and motor (Kimble Chase, no. 749540-0000). Western immunoblots were run using a standard protocol with Invitrogen's XCell SureLock blot system, 4-12% Bis-Tris NuPAGE gels. For Gmr-GAL4, an iBlot dry transfer system with nitrocellulose membranes was used. For DaGS, a standard wet transfer using the XCell blot system was performed with polyvinylidene difluoride membrane.
iPS cell lysates and reagents. iPS cells (described in Supplementary Fig. 10a ) were cultured as previously described 68 , and lysates were prepared using RIPA buffer plus 1× protease and phosphotase inhibitors. Samples (20 μg of total protein per lane) were run using a standard western immunoblot protocol with Invitrogen's XCell SureLock blot system, 4-12% Bis-Tris NuPAGE gels, and wet transfer with polyvinylidene difluoride membrane.
Mouse lysates and reagents. Mice expressing either (G4C2) 2 or (G4C2) 149 were generated by intracerebroventricular administration of AAV2/9 vectors, as previously described 51 . Cortical tissues were collected at 3 months and 6 months. Protein lysates were prepared using a 1:5 weight/volume of ice-cold buffer (50 mM Tris pH 7.4, 50 mM NaCl, 1 mM EDTA) with 2× protease and phosphatase inhibitors. A solution of 1% Triton X-100 and 2% SDS was added. Tissue homogenates were sonicated on ice and centrifuged at 4 °C for 20 min at 16,000 × g. Samples (30 μg of total protein per lane) were run using a standard western immunblot protocol with 10% Tris-Glycine gels and wet transfer with nitrocellulose membrane.
Fly antibodies. Anti-β-Galactosidase (Promega, no. Z3781, 1:2,000), anti-TDP43 (ProteinTech, no. 10782-2-AP, 1:2,000) and anti-α-Tubulin (DSHB, no. AA4.3, 1:2,000) were used 23, 35, 54, 62 . dCDC73-specific and dRtf1-specific antibodies were developed as previously described 69 .
Mammalian antibodies. Anti-Paf1 (Cell Signaling, no. 12883, 1:1,000) 39 , antiLeo1 (ProteinTech, no. 12281-1-AP, 1:2,000), anti-CDC73 (Cell Signaling, no. 8126, 1:2,000) 70 , anti-Rtf1 (Cell Signaling, no. 14737, 1:2,000), anti-α-Tubulinhorseradish peroxidase (Cell Signaling, no. 9099, 1:2,000), and anti-GAPDH (iPS cells: Abcam, no. G8795, 1:5,000; mice: Meridian Life Science, no. H86504M, 1:10,000) were used. Anti-Paf1, anti-Leo1, and anti-Rtf1 antibodies were validated using short interfering RNA (siRNA)-mediated knockdown of individual genes in fibroblast cells (data not shown).
Secondary antibodies and imaging. Mouse or rabbit horseradish peroxidaseconjugated secondary antibodies (Jackson Immunoresearch Labs, no. 115-035-146 and no. 111-035-144) were used at 1:5,000 23, 35, 54, 62 . Blots were analyzed using Amersham ECL Prime Detection Reagent and imaged on an Amersham Imager 600.
Real-time qPCR. All primers are defined in Supplementary Table 4 .
Flies. Total RNA was collected using TRIzol. For DaGS or Da-GAL4 assays, biological triplicate samples of ten whole animals were processed per condition. For ElavGS assays, biological triplicate samples of 20-30 fly heads (16 days old) were processed per condition. qPCR experiments were run using standard protocols. Complementary DNA was made from 200-400 ng of total RNA using random primers and a High Capacity cDNA Reverse Transcription kit (ThermoFisher, no. 4368814). qPCR reactions were setup using SYBR Green Fast reagents, 384-well plates, and analyzed on a ViiA 7 Real-Time PCR System (Applied Biosystems) for all samples in duplicate. The mean fold change was determined using the ∆∆Ct method, comparing relative expression to control (mean = 1). The housekeeping gene RP49 (RNAPI-driven) was used, while preliminary work showed data to be consistent using multiple housekeeping genes. Primers targeting the G4C2 fly transgenes utilized unique restriction enzyme sequences in our construct found immediately 3′ of the repeat ( Supplementary  Fig. 12a ). All primers were validated using a serial dilution curve. Supplementary  Fig. 12 shows that the primer efficiencies between G4C2 and the loading control used, RP49, were similar.
Humans. Total RNA was extracted from frozen postmortem tissue from the frontal cortex using a RNAeasy Plus Mini kit (Qiagen), as previously described 71 . RNA integrity (RIN) was verified on an Agilent 2100 Bioanalyzer. qPCR experiments were run using standard protocols. cDNA was made from 500 ng of total RNA (RIN ≥ 7.0, mean RIN for all samples = 9.3) using random primers and a High Capacity cDNA Reverse Transcription kit (ThermoFisher). qPCR was conducted using SYBR GreenER qPCR SuperMix (Invitrogen) for all samples in triplicate. qPCR experiments were run in an ABI Prism 7900HT Fast Real-Time PCR System (Applied Biosystems). The mean fold change was determined using the ∆∆Ct method, comparing relative expression to healthy controls (mean = 1). Housekeeping genes included RPLP0 and GAPDH. Primers targeting the C9orf72 transcript have been previously described 72 .
Yeast. Centromeric galactose-inducible plasmids that express C9orf72 hexanucleotide repeats-sense (G4C2) 66 or antisense (G2C4) 66 -were transformed into yeast, as previously described 23 . Overnight cultures were grown from transformants in 2% raffinose-containing media, diluted into 2% galactosecontaining liquid media the next morning and further grown at 30 °C for 6 h to allow for transgene expression. RNA was collected from these cultures using a MasterPure Yeast RNA Extraction kit (Lucigen), including DNAseI digestions during the purification. Equal amounts of RNA were reverse transcribed using a High-Capacity cDNA Reverse Transcription kit (Applied Biosystems) and analyzed by qPCR using SYBR Green reagents.
External fly eye GR-GFP imaging. y 1 sc* v 1 ;; Gmr-GAL4, UAS-LDS-(G4C2) 44 GR-GFP animals were crossed to RNAi lines or controls. Heads from 1-2-day-old progeny were isolated and positioned for imaging on a glass slide using Vaseline. GFP imaging was immediately performed on a Leica DM6000B microscope using Zstacks. Total GFP fluorescence in the compiled images was measured in ImageJ and normalized relative to control. Only expanded (G4C2) 30+ transgenes produce GR-GFP; lines containing ≤ 22 repeats exhibit no GFP signal, as assessed by external eye fluorescence imaging or by western immunoblotting (data not shown).
Yeast strains and spotting assays. All yeast strains are derivatives of the haploid wild-type BY4741 strain, and all deletion strains were verified by PCR genotyping and qPCR. Centromeric galactose-inducible plasmids expressing codon-optimized C9orf72 dipeptide repeat proteins, (PR) 50 and (GR) 100 (refs. 23, 73, 74 ), or a control protein (CCDB) were transformed into yeast using standard methods and selected for on SD-URA agar plates. For serial dilution growth analysis, transformants were grown overnight in 2% raffinose-containing media. Overnight cultures were all normalized to OD 600 = 0.8, and then each strain was diluted serially fivefold in a 96-well plate. Yeast cultures were spotted onto either 2% glucose-or 2% galactosecontaining agar plates with a multipin 'frogger' and allowed to grow for 48 h at 30 °C before being photographed. Supplementary  Fig. 10a ) were cultured in a standard 37 °C, 5% CO 2 incubator using DMEM medium (with L-glutamine, high glucose, and sodium pyruvate) supplemented with 15% heat-inactivated fetal bovine serum, 1% amino acids, and 1% penicillinstreptomycin. For ChIP, half of the cells were collected from a confluent T-75 flask using trypsin, washed in Dulbecco's PBS and fixed in 1.1% formaldehyde for 10 min. ChIP assays were then performed as previously described 75 , but with the following details. DNA was fragmented using a bucket sonicator for 20 min. Dynabeads protein A (Invitrogen, no. 10001D) were used at 30 μl per immunoprecipitation. The primary antibody against hLeo1 (ProteinTech, no. 12281-1-AP) was used at 5 μg per 100 μg DNA, with overnight incubation. After an overnight decrosslinking step, DNA was isolated using a standard phenol-chloroform-isoamyl alcohol protocol into 50 μl. A volume of 4 μl was run per quadruplicate reaction by qPCR using SYBR Green. Mean Ct values were normalized to input and transformed relative to Rb IgG control (Cell Signaling, no. 2729). The intergenic sequence was as previously described 76 . A positive control gene, p21, was used to validate Leo1 ChIP efficacy 38 . All primers are defined in Supplementary Table 4 .
Fibroblast cells and ChIP. Primary fibroblast cells (described in
Statistical analysis, sampling, and randomization. GraphPad Prism v.7.00 or v.8.00 software was used to generate all graphs and for all statistical analyses. P values of < 0.05 were considered significant. See Supplementary Table 1 for details on statistics and the Life Sciences Reporting Summary for additional information. No data were excluded from this study.
Flies, yeast, mice, and cell lines. Data were assumed to be normal. Two-tailed unpaired Student t-tests, one-way analysis of variance (ANOVA), or two-way ANOVA statistical analyses were performed when appropriate based on the experimental design. For ANOVA, Tukey's multiple comparisons tests were predominantly used. No statistical methods were used to predetermine sample sizes, but numbers were similar to previous work 23 , 34, 52, 60, 61 . Researchers were blinded to the genotype of all samples to maintain unbiased scoring.
Humans. Data were found to not fit a normal distribution. Kruskal-Wallis one-way ANOVA with Dunn's multiple comparison tests were performed to assess changes in the expression of genes. Follow-up Spearman r correlations were performed. No statistical methods were used to predetermine sample sizes, but numbers were similar to previous work 23, 71, 77 . Researchers were not blinded as data are inherently unbiased.
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Human research participants
Policy information about studies involving human research participants
Population characteristics
Post-mortem tissue was taken from the frontal cortex of healthy, FTD, FTD/ALS, or ALS cases with or without the C9orf72-mutation. Tissue was obtained from the Mayo Clinic Florida Brain Bank. Patient information is clearly described in Supplementary Fig. 10c . In summary, data included 67 C9+ cases (53% male, age of onset = 61, age at death =64, disease duration = 3.7), 56 C9-cases (44% male, age of onset = 66, age at death = 73, disease duration = 4.3), 27 healthy individuals (15% male, age at death = 81).
Recruitment recruitment was performed based on IRB regulations with no anticipated biases Ethics oversight
Protocols were approved by the Mayo Clinic Institutional Review Board and Ethics Committee.
Note that full information on the approval of the study protocol must also be provided in the manuscript.
